Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Teva Pharmaceutical Industries ADR (TEVA)

Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,757,176
  • Shares Outstanding, K 1,146,960
  • Annual Sales, $ 16,544 M
  • Annual Income, $ -1,639 M
  • EBIT $ 2,416 M
  • EBITDA $ 3,475 M
  • 60-Month Beta 0.67
  • Price/Sales 1.96
  • Price/Cash Flow 8.42
  • Price/Book 4.48

Options Overview Details

View History
  • Implied Volatility 26.66% (-4.02%)
  • Historical Volatility 58.44%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 80.64% on 09/09/25
  • IV Low 26.66% on 12/10/25
  • Expected Move (DTE 1) 0.19 (0.63%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 20,988
  • Volume Avg (30-Day) 26,156
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 833,808
  • Open Int (30-Day) 825,038
  • Expected Range 29.61 to 29.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.64
  • Number of Estimates 4
  • High Estimate 0.67
  • Low Estimate 0.61
  • Prior Year 0.70
  • Growth Rate Est. (year over year) -8.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.01 +24.11%
on 11/21/25
29.80 unch
on 12/10/25
+5.54 (+22.84%)
since 11/10/25
3-Month
18.21 +63.65%
on 09/25/25
29.80 unch
on 12/10/25
+10.23 (+52.27%)
since 09/10/25
52-Week
12.47 +139.07%
on 04/10/25
29.80 unch
on 12/10/25
+12.45 (+71.76%)
since 12/10/24

Most Recent Stories

More News
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Enovis (ENOV) and Healthequity (HQY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA – Research Report), Enovis (ENOV – Research Report) and Healthequity (HQY...

ENOV : 27.67 (+2.33%)
HQY : 95.73 (+2.65%)
TEVA : 29.80 (+4.34%)
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson’s JNJ stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since mid-June. It achieved the golden cross in mid-July, after the company announced strong...

JNJ : 206.54 (+3.29%)
KVUE : 17.32 (+1.76%)
TEVA : 29.80 (+4.34%)
AMGN : 315.38 (+0.49%)
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we discuss...

JNJ : 206.54 (+3.29%)
TEVA : 29.80 (+4.34%)
AMGN : 315.38 (+0.49%)
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product,...

JNJ : 206.54 (+3.29%)
KVUE : 17.32 (+1.76%)
TEVA : 29.80 (+4.34%)
AMGN : 315.38 (+0.49%)
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

Johnson & Johnson’s JNJ second-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.66. Earnings, however, declined 1.8% from the year-ago period.Adjusted...

JNJ : 206.54 (+3.29%)
KVUE : 17.32 (+1.76%)
TEVA : 29.80 (+4.34%)
AMGN : 315.38 (+0.49%)
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months.  Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics,...

JNJ : 206.54 (+3.29%)
TEVA : 29.80 (+4.34%)
AMGN : 315.38 (+0.49%)
SNY : 48.26 (+0.90%)
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

/CNW/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in...

ONCY : 0.9896 (+1.31%)
ADCT : 4.01 (+13.60%)
TEVA : 29.80 (+4.34%)
CTOR : 1.1300 (-2.59%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.9900 (+1.53%)
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END

ONCY : 0.9896 (+1.31%)
ADCT : 4.01 (+13.60%)
TEVA : 29.80 (+4.34%)
CTOR : 1.1300 (-2.59%)
ONC.TO : 1.42 (+2.16%)
OSTX : 1.9900 (+1.53%)
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

FLUT : 218.34 (+1.08%)
TEVA : 29.80 (+4.34%)
DOCU : 68.81 (-0.84%)
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value.J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity...

JNJ : 206.54 (+3.29%)
KVUE : 17.32 (+1.76%)
TEVA : 29.80 (+4.34%)
AMGN : 315.38 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets,...

See More

Key Turning Points

3rd Resistance Point 31.12
2nd Resistance Point 30.46
1st Resistance Point 30.13
Last Price 29.80
1st Support Level 29.14
2nd Support Level 28.48
3rd Support Level 28.15

See More

52-Week High 29.80
Last Price 29.80
Fibonacci 61.8% 23.18
Fibonacci 50% 21.13
Fibonacci 38.2% 19.09
52-Week Low 12.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar